JP2010163438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010163438A5 JP2010163438A5 JP2010030683A JP2010030683A JP2010163438A5 JP 2010163438 A5 JP2010163438 A5 JP 2010163438A5 JP 2010030683 A JP2010030683 A JP 2010030683A JP 2010030683 A JP2010030683 A JP 2010030683A JP 2010163438 A5 JP2010163438 A5 JP 2010163438A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- composition
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims 37
- 210000004881 tumor cell Anatomy 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 102000012545 EGF-like domains Human genes 0.000 claims 2
- 108050002150 EGF-like domains Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28678201P | 2001-04-26 | 2001-04-26 | |
| US29302001P | 2001-05-17 | 2001-05-17 | |
| US30109101P | 2001-06-26 | 2001-06-26 | |
| US36700202P | 2002-03-22 | 2002-03-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009025420A Division JP4575983B2 (ja) | 2001-04-26 | 2009-02-05 | Ｃｒｉｐｔｏをブロックする抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010163438A JP2010163438A (ja) | 2010-07-29 |
| JP2010163438A5 true JP2010163438A5 (enExample) | 2011-04-07 |
Family
ID=27501437
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002585468A Expired - Fee Related JP4307845B2 (ja) | 2001-04-26 | 2002-04-17 | Ｃｒｉｐｔｏをブロックする抗体およびその使用 |
| JP2005202361A Pending JP2005314436A (ja) | 2001-04-26 | 2005-07-11 | Ｃｒｉｐｔｏをブロックする抗体およびその使用 |
| JP2009025420A Expired - Fee Related JP4575983B2 (ja) | 2001-04-26 | 2009-02-05 | Ｃｒｉｐｔｏをブロックする抗体およびその使用 |
| JP2010030683A Withdrawn JP2010163438A (ja) | 2001-04-26 | 2010-02-15 | Ｃｒｉｐｔｏをブロックする抗体およびその使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002585468A Expired - Fee Related JP4307845B2 (ja) | 2001-04-26 | 2002-04-17 | Ｃｒｉｐｔｏをブロックする抗体およびその使用 |
| JP2005202361A Pending JP2005314436A (ja) | 2001-04-26 | 2005-07-11 | Ｃｒｉｐｔｏをブロックする抗体およびその使用 |
| JP2009025420A Expired - Fee Related JP4575983B2 (ja) | 2001-04-26 | 2009-02-05 | Ｃｒｉｐｔｏをブロックする抗体およびその使用 |
Country Status (33)
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090123470A1 (en) * | 2001-03-26 | 2009-05-14 | The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. | Antibodies Against Cancer |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| CZ20033208A3 (en) | 2001-04-26 | 2004-03-17 | Biogen, Inc. | Cripto blocking antibodies and uses thereof |
| EP1494693B1 (en) * | 2002-03-22 | 2010-12-08 | Biogen Idec MA Inc. | Cripto-specific antibodies |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| AU2004274433B2 (en) | 2003-09-15 | 2010-08-12 | Research Development Foundation | Cripto antagonism of activin and TGF-beta signaling |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| CA2593212A1 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Cripto binding molecules |
| JP5693004B2 (ja) * | 2006-07-28 | 2015-04-01 | チルドレンズ メモリアル ホスピタル | ヒト胚性幹細胞の微小環境を使用して腫瘍細胞の悪性度を抑制する方法 |
| AU2008260445A1 (en) * | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| WO2009131852A1 (en) * | 2008-04-21 | 2009-10-29 | Merck & Co., Inc. | Pancreatic beta-cell mass biomarker |
| CN102272157B (zh) * | 2008-11-07 | 2015-11-25 | 研究发展基金会 | 用于抑制cripto/grp78复合物形成和信号的组合物和方法 |
| AU2010292172A1 (en) | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| CA3220104A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| WO2012123755A1 (en) | 2011-03-17 | 2012-09-20 | The University Of Birmingham | Re-directed immunotherapy |
| SG194567A1 (en) | 2011-04-21 | 2013-12-30 | Seattle Genetics Inc | Novel binder-drug conjugates (adcs) and their use |
| EP2707723B1 (en) | 2011-05-12 | 2016-02-10 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| JP6104257B2 (ja) | 2011-10-14 | 2017-03-29 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンおよびそのコンジュゲート |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| BR112015008238A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolbenzodiazepina-anticorpo anti-cd22 |
| KR101995620B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
| EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| DK2906298T3 (en) | 2012-10-12 | 2018-12-17 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| PT2906253T (pt) | 2012-10-12 | 2018-11-05 | Medimmune Ltd | Conjugados de anticorpo anti-psma de pirrolobenzodiazepina |
| US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| ES2687439T3 (es) | 2013-03-13 | 2018-10-25 | Medimmune Limited | Pirrolobenzodiazepinas y conjugados de las mismas |
| MX363787B (es) | 2013-03-13 | 2019-04-03 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de los mismos. |
| KR102066318B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| BR112016002829A2 (pt) | 2013-08-12 | 2017-09-19 | Genentech Inc | Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| BR112016012410A2 (pt) | 2013-12-16 | 2017-09-26 | Genentech Inc | conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica |
| UA118113C2 (uk) | 2013-12-16 | 2018-11-26 | Дженентек, Інк. | Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом |
| JP6980384B2 (ja) | 2013-12-16 | 2021-12-15 | ジェネンテック， インコーポレイテッド | １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法 |
| AU2014372833B2 (en) | 2013-12-23 | 2019-08-22 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| JP2017531620A (ja) | 2014-09-12 | 2017-10-26 | ジェネンテック， インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| JP2017533887A (ja) | 2014-09-17 | 2017-11-16 | ジェネンテック， インコーポレイテッド | ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| CA2980611A1 (en) * | 2015-04-07 | 2016-10-13 | Paranta Biosciences Limited | A method of treating neoplasias |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| SG11201710639YA (en) | 2015-06-22 | 2018-01-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| CR20180243A (es) | 2015-10-02 | 2018-07-31 | Genentech Inc | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| JP6852065B2 (ja) | 2015-10-20 | 2021-03-31 | ジェネンテック， インコーポレイテッド | カリケアマイシン−抗体−薬物コンジュゲート及び使用方法 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| SG10202008909VA (en) | 2016-03-24 | 2020-10-29 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
| JP7043425B2 (ja) | 2016-06-06 | 2022-03-29 | ジェネンテック， インコーポレイテッド | シルベストロール抗体－薬物コンジュゲート及び使用方法 |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
| AU2017380871C1 (en) | 2016-12-21 | 2025-05-15 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| RS61795B1 (sr) | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin antitela |
| SMT202200490T1 (it) | 2017-04-18 | 2023-01-13 | Medimmune Ltd | Coniugati di pirrolobenzodiazepina |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| KR102442736B1 (ko) | 2017-06-14 | 2022-09-16 | 에이디씨 테라퓨틱스 에스에이 | 항-cd19 adc의 투여를 위한 투약량 체제 |
| SI3668874T1 (sl) | 2017-08-18 | 2022-04-29 | Medimmune Limited | Pirolobenzodiazepinski konjugati |
| ES3075078T3 (es) | 2017-09-20 | 2026-07-27 | Ph Pharma Co Ltd | Análogos de tailanstatina |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CN119405833A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
| CN120189526A (zh) | 2018-12-13 | 2025-06-24 | 卫材R&D管理有限公司 | 荷伯希二烯抗体-药物缀合物及使用方法 |
| JP7728701B2 (ja) | 2018-12-17 | 2025-08-25 | レビトープ リミテッド | 双子型免疫細胞エンゲージャー |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| JP7232925B2 (ja) | 2019-02-15 | 2023-03-03 | ウーシー バイオロジクス アイルランド リミテッド | 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
| CN120417934A (zh) | 2022-12-23 | 2025-08-01 | 基因泰克公司 | Cereblon降解剂缀合物及其用途 |
| KR20260012304A (ko) | 2023-04-17 | 2026-01-26 | 피크 바이오, 인크. | 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체 |
| CN122497691A (zh) * | 2023-12-19 | 2026-07-31 | 百欧恩泰欧洲股份公司 | Cfc1结合分子 |
| AU2024404304A1 (en) * | 2023-12-19 | 2026-05-21 | BioNTech SE | Cfc1 binding molecule |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
| TW202617186A (zh) | 2024-06-28 | 2026-05-01 | 美商飛爾富來生物公司 | Ｂｃｌ－ｘｌ降解劑抗體結合物及其用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) * | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5780029A (en) | 1989-11-14 | 1998-07-14 | New York Medical College | Antidiotypic monoclonal antibodies for treatment of melanoma |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5264557A (en) | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US6063379A (en) | 1993-12-09 | 2000-05-16 | Centro De Inmunologia Molecular | Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies |
| US5981215A (en) * | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| BR9710811A (pt) * | 1996-05-22 | 1999-08-17 | Novopharm Biotech Inc | Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| AU754808B2 (en) | 1999-03-30 | 2002-11-28 | Amgen Fremont Inc. | Method for preparing Monoclonal Antibody |
| EP1179178A1 (en) * | 1999-04-20 | 2002-02-13 | William J. Kokolus | Improved method of identifying and locating immunobiologically-active linear peptides |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| JP2001046066A (ja) | 1999-08-03 | 2001-02-20 | Kyowa Hakko Kogyo Co Ltd | 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体 |
| KR100490077B1 (ko) | 1999-10-29 | 2005-05-17 | 제넨테크, 인크. | 항-전립선 줄기세포 항원 (ｐｓｃａ) 항체 조성물 및 그의사용 방법 |
| US6663613B1 (en) | 2000-01-25 | 2003-12-16 | Bacchus Vascular, Inc. | System and methods for clot dissolution |
| SI1270595T1 (sl) | 2000-03-03 | 2008-12-31 | Kyowa Hakko Kogyo Kk | Protitelo proti CCR4 in njegov fragment |
| US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| NZ525380A (en) | 2000-09-18 | 2008-06-30 | Biogen Idec Inc | Non-fucosylated forms of Cripto and their use as tumor blocking agents |
| EP1370869B1 (en) | 2001-01-26 | 2006-12-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Detection and quantification of cripto-1 |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| BR0206985A (pt) | 2001-01-29 | 2005-04-19 | Idec Pharma Corp | Anticorpos modificados e métodos de uso |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| CZ20033208A3 (en) | 2001-04-26 | 2004-03-17 | Biogen, Inc. | Cripto blocking antibodies and uses thereof |
| NZ573739A (en) * | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201 |
| US20040014690A1 (en) * | 2002-02-13 | 2004-01-22 | Zhenkun Ma | Macrolides with activity against methicillin-resistant staphylococcus aureus |
| EP1494693B1 (en) * | 2002-03-22 | 2010-12-08 | Biogen Idec MA Inc. | Cripto-specific antibodies |
| AU2004274433B2 (en) * | 2003-09-15 | 2010-08-12 | Research Development Foundation | Cripto antagonism of activin and TGF-beta signaling |
| CA2593212A1 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Cripto binding molecules |
| US20100041032A1 (en) * | 2006-04-28 | 2010-02-18 | Biogen Idec Ma Inc. | Composition and methods for the detection of cripto-3 |
-
2002
- 2002-04-17 CZ CZ20033208A patent/CZ20033208A3/cs unknown
- 2002-04-17 ES ES02731384T patent/ES2321065T3/es not_active Expired - Lifetime
- 2002-04-17 MX MXPA03009797A patent/MXPA03009797A/es active IP Right Grant
- 2002-04-17 WO PCT/US2002/011950 patent/WO2002088170A2/en not_active Ceased
- 2002-04-17 AT AT08158456T patent/ATE533508T1/de active
- 2002-04-17 CA CA2443840A patent/CA2443840C/en not_active Expired - Fee Related
- 2002-04-17 JP JP2002585468A patent/JP4307845B2/ja not_active Expired - Fee Related
- 2002-04-17 EP EP02731384A patent/EP1390389B1/en not_active Expired - Lifetime
- 2002-04-17 AT AT02731384T patent/ATE420659T1/de active
- 2002-04-17 DK DK02731384T patent/DK1390389T3/da active
- 2002-04-17 RS YU84903A patent/RS51635B/sr unknown
- 2002-04-17 KR KR1020037014078A patent/KR100592357B1/ko not_active Expired - Fee Related
- 2002-04-17 HU HU0501113A patent/HUP0501113A3/hu unknown
- 2002-04-17 TR TR2003/01846T patent/TR200301846T2/xx unknown
- 2002-04-17 CA CA2715570A patent/CA2715570A1/en not_active Abandoned
- 2002-04-17 SI SI200230804T patent/SI1390389T1/sl unknown
- 2002-04-17 EE EEP200300528A patent/EE200300528A/xx unknown
- 2002-04-17 SK SK1443-2003A patent/SK14432003A3/sk not_active Application Discontinuation
- 2002-04-17 DE DE60230868T patent/DE60230868D1/de not_active Expired - Lifetime
- 2002-04-17 RS RS20110024A patent/RS20110024A/sr unknown
- 2002-04-17 GE GE5415A patent/GEP20074091B/en unknown
- 2002-04-17 NZ NZ566268A patent/NZ566268A/en not_active IP Right Cessation
- 2002-04-17 CN CNB028128877A patent/CN100352501C/zh not_active Expired - Fee Related
- 2002-04-17 BR BRPI0209254-9A patent/BR0209254A/pt not_active IP Right Cessation
- 2002-04-17 PT PT02731384T patent/PT1390389E/pt unknown
- 2002-04-17 SG SG200600551-6A patent/SG157951A1/en unknown
- 2002-04-17 EA EA200301158A patent/EA007469B1/ru not_active IP Right Cessation
- 2002-04-17 PL PL373513A patent/PL207087B1/pl unknown
- 2002-04-17 EP EP10186149A patent/EP2316486A3/en not_active Withdrawn
- 2002-04-17 EP EP08158456A patent/EP1974749B1/en not_active Expired - Lifetime
- 2002-04-23 MY MYPI2010003173A patent/MY150237A/en unknown
- 2002-04-23 MY MYPI20021484A patent/MY157382A/en unknown
- 2002-04-24 AR ARP020101492A patent/AR037223A1/es active IP Right Grant
-
2003
- 2003-10-23 US US10/693,538 patent/US7531174B2/en not_active Expired - Lifetime
- 2003-10-24 IS IS6999A patent/IS2662B/is unknown
- 2003-10-27 NO NO20034805A patent/NO20034805L/no not_active Application Discontinuation
- 2003-11-14 BG BG108363A patent/BG108363A/bg unknown
-
2005
- 2005-07-11 JP JP2005202361A patent/JP2005314436A/ja active Pending
-
2007
- 2007-04-30 US US11/799,361 patent/US7674462B2/en not_active Expired - Lifetime
-
2008
- 2008-12-22 US US12/317,476 patent/US8003763B2/en not_active Expired - Lifetime
-
2009
- 2009-01-14 US US12/353,913 patent/US20090285818A1/en not_active Abandoned
- 2009-02-05 JP JP2009025420A patent/JP4575983B2/ja not_active Expired - Fee Related
- 2009-03-31 US US12/415,659 patent/US7888052B2/en not_active Expired - Lifetime
- 2009-04-08 CY CY20091100413T patent/CY1108960T1/el unknown
- 2009-07-08 AR ARP090102597A patent/AR072554A2/es not_active Application Discontinuation
- 2009-12-22 CL CL2009002199A patent/CL2009002199A1/es unknown
-
2010
- 2010-02-15 JP JP2010030683A patent/JP2010163438A/ja not_active Withdrawn
- 2010-07-16 AR ARP100102604A patent/AR077759A2/es not_active Application Discontinuation
-
2011
- 2011-08-19 US US13/213,499 patent/US8673303B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240239882A1 (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) | |
| JP2004534020A5 (enExample) | ||
| JP2009108100A5 (enExample) | ||
| ES2664809T3 (es) | Anticuerpo anti-TROP-2 humano que tiene actividad antitumoral in vivo | |
| CA2443840A1 (en) | Cripto blocking antibodies and uses thereof | |
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| JP2012523848A5 (enExample) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| JP2014524746A5 (enExample) | ||
| WO2012135854A3 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
| JP2016187356A5 (enExample) | ||
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| JP2009505676A5 (enExample) | ||
| JP2007536932A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| CN109963592A (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2012502938A5 (enExample) | ||
| JP2005520566A5 (enExample) | ||
| JP2010006705A5 (enExample) | ||
| JP2020503252A5 (enExample) | ||
| ES2537017T9 (es) | Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano | |
| EP4613334A3 (en) | Her-2 binding antibodies | |
| JP2014223083A5 (enExample) |